We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP). Exclusion criteria included serum creatinine ≥ 2.5 mg/dL. In the VMPT-VT/VMP arms, severe RI (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min), moderate RI (eGFR 31-50 mL/min), and normal renal function (eGFR > 50 mL/min), were 6%/7.9%, 24.1%/24.9%, and 69.8%/67.2%, respectively. Statistically significant improvements in overall response rates and progression-free survival were observed in VMPT-VT versus VMP arms across renal cohorts, except in severe RI patients. In the VMPT group, severe RI reduced overall survival (OS). RI was reversed in 16/63 (25.4%) patients receiving VMPT-VT versus 31/77 (40.3%) receiving VMP. Multivariate analysis showed male sex (P = .022) and moderate RI (P = .003) significantly predicted RI recovery. VMP patients achieving renal response showed longer OS. In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected. VMPT-VT was superior to VMP for cases with normal renal function and moderate RI, whereas VMPT-VT failed to outperform VMP in patients with severe RI, although the relatively low number of cases analyzed preclude drawing definitive conclusions. VMPT-VT had no advantage in terms of RI reversal over VMP. This study is registered at http://www.clinicaltrials.gov as NCT01063179.

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment / Morabito, F; Gentile, M; Mazzone, C; Rossi, D; Di Raimondo, F; Bringhen, S; Ria, R; Offidani, M; Patriarca, F; Nozzoli, C; Petrucci, Mt; Benevolo, G; Vincelli, I; Guglielmelli, T; Grasso, M; Marasca, Roberto; Baldini, L; Montefusco, V; Musto, P; Cascavilla, N; Majolino, I; Musolino, C; Cavo, M; Boccadoro, M; Palumbo, A.. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 118:(2011), pp. 5759-5766. [10.1182/blood-2011-05-353995]

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

MARASCA, Roberto;
2011

Abstract

We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP). Exclusion criteria included serum creatinine ≥ 2.5 mg/dL. In the VMPT-VT/VMP arms, severe RI (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min), moderate RI (eGFR 31-50 mL/min), and normal renal function (eGFR > 50 mL/min), were 6%/7.9%, 24.1%/24.9%, and 69.8%/67.2%, respectively. Statistically significant improvements in overall response rates and progression-free survival were observed in VMPT-VT versus VMP arms across renal cohorts, except in severe RI patients. In the VMPT group, severe RI reduced overall survival (OS). RI was reversed in 16/63 (25.4%) patients receiving VMPT-VT versus 31/77 (40.3%) receiving VMP. Multivariate analysis showed male sex (P = .022) and moderate RI (P = .003) significantly predicted RI recovery. VMP patients achieving renal response showed longer OS. In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected. VMPT-VT was superior to VMP for cases with normal renal function and moderate RI, whereas VMPT-VT failed to outperform VMP in patients with severe RI, although the relatively low number of cases analyzed preclude drawing definitive conclusions. VMPT-VT had no advantage in terms of RI reversal over VMP. This study is registered at http://www.clinicaltrials.gov as NCT01063179.
118
5759
5766
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment / Morabito, F; Gentile, M; Mazzone, C; Rossi, D; Di Raimondo, F; Bringhen, S; Ria, R; Offidani, M; Patriarca, F; Nozzoli, C; Petrucci, Mt; Benevolo, G; Vincelli, I; Guglielmelli, T; Grasso, M; Marasca, Roberto; Baldini, L; Montefusco, V; Musto, P; Cascavilla, N; Majolino, I; Musolino, C; Cavo, M; Boccadoro, M; Palumbo, A.. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 118:(2011), pp. 5759-5766. [10.1182/blood-2011-05-353995]
Morabito, F; Gentile, M; Mazzone, C; Rossi, D; Di Raimondo, F; Bringhen, S; Ria, R; Offidani, M; Patriarca, F; Nozzoli, C; Petrucci, Mt; Benevolo, G; Vincelli, I; Guglielmelli, T; Grasso, M; Marasca, Roberto; Baldini, L; Montefusco, V; Musto, P; Cascavilla, N; Majolino, I; Musolino, C; Cavo, M; Boccadoro, M; Palumbo, A.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/695084
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 29
social impact